Discontinued — last reported Q1 '26
RotaTeq — Sales
Merck & Co. RotaTeq — Sales decreased by 13.8% to $206.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 54.8%, from $456.00M to $206.00M. Over 4 years (FY 2021 to FY 2025), RotaTeq — Sales shows a downward trend with a -4.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market adoption, effective distribution, or successful competitive positioning, while a decrease may indicate patent expiration, increased competition from alternative vaccines, or shifts in public health immunization policies.
Detailed definition
This metric represents the total annual revenue generated from the sale of a specific vaccine product line designed to p...
Peer comparison
Comparable to revenue metrics for specific branded pharmaceutical or vaccine products at peer companies, often evaluated against the backdrop of patent cliffs and market penetration rates.
mrk_segment_rotateq_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $416.00M | $454.00M | $427.00M | $432.00M | $346.00M | $512.00M | $276.00M | $594.00M | $261.00M | $312.00M | $371.00M | $432.00M | $326.00M | $386.00M | $278.00M | $456.00M | $242.00M | $408.00M | $239.00M | $206.00M |
| QoQ Change | — | +9.1% | -5.9% | +1.2% | -19.9% | +48.0% | -46.1% | +115.2% | -56.1% | +19.5% | +18.9% | +16.4% | -24.5% | +18.4% | -28.0% | +64.0% | -46.9% | +68.6% | -41.4% | -13.8% |
| YoY Change | — | — | — | — | -16.8% | +12.8% | -35.4% | +37.5% | -24.6% | -39.1% | +34.4% | -27.3% | +24.9% | +23.7% | -25.1% | +5.6% | -25.8% | +5.7% | -14.0% | -54.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s rotateq — sales?
- Merck & Co. (MRK) reported rotateq — sales of $206.00M in Q1 2026.
- How has Merck & Co.'s rotateq — sales changed year-over-year?
- Merck & Co.'s rotateq — sales decreased by 54.8% year-over-year, from $456.00M to $206.00M.
- What is the long-term trend for Merck & Co.'s rotateq — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s rotateq — sales has grown at a -4.5% compound annual growth rate (CAGR), from $1.61B to $1.35B.
- What does rotateq — sales mean?
- The total annual revenue generated from the sale of the company's rotavirus vaccine product.